OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Lallas on the Future of Immunotherapy in Genitourinary Malignancies

August 30th 2017

Costas Lallas, MD, professor at Sidney Kimmel Medical College, Thomas Jefferson University Hospital, discusses the future of immunotherapy in patients with genitourinary malignancies.

Dr. du Bois on the Potential Impact of Cytoreductive Surgery in Ovarian Cancer

August 29th 2017

Andreas du Bois, MD, PhD, a professor of gynecologic oncology at Kliniken Essen Mitte, discusses the potential impact of cytoreductive surgery in ovarian cancer.

Dr. Campbell Discusses Advancements in Kidney Cancer Management

August 29th 2017

Steven Campbell, MD, PhD, urologist, Cleveland Clinic, discusses recent advancements in the management of kidney cancer.

Dr. Loeb on the Results of Active Surveillance for Prostate Cancer

August 29th 2017

Stacy Loeb, MD, assistant professor of urology and population health at NYU Langone School of Medicine, discusses the results and impact of active surveillance on patients with prostate cancer.

Dr. Rugo on the Future of Extended Adjuvant Hormone Therapy for Breast Cancer

August 29th 2017

Hope S. Rugo, MD, a professor of medicine and director of the Breast Oncology Clinical Trials Program, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco discusses the future of extended adjuvant hormone therapy for patients with breast cancer.

Dr. Vokes on PARP Inhibitors for NSCLC

August 29th 2017

Everett Vokes, MD, John E. Ultmann Professor of Medicine and Radiation Oncology, physician-in-chief, chair, Department of Medicine, University of Chicago Medicine, discusses PARP inhibitors for patients with non-small cell lung cancer (NSCLC).

Dr. Nanus on Cytoreductive Nephrectomy for RCC

August 28th 2017

David M. Nanus, MD, medical oncologist, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses cytoreductive nephrectomy for patients with renal cell carcinoma (RCC).

Dr. Siegel on Induction Therapy for Head and Neck Cancer

August 28th 2017

Robert Siegel, MD, chair, professor of medicine, director, Division of Hematology/Oncology, George Washington University, discusses induction therapy for head and neck cancer.

Dr. Nowakowski on Using Patient Performance Score and Age for MCL Treatment

August 28th 2017

Grzegorz S. Nowakowski, MD, assistant professor of medicine at Mayo Clinic, discusses the use of patient performance status and age to make treatment decisions for patients with mantle cell lymphoma (MCL).

Dr. Sartor on Conclusions and Future of Sipuleucel-T in Prostate Cancer

August 28th 2017

Oliver Sartor, MD, medical oncologist at Tulane University School of Medicine, discusses conclusions drawn from an analysis of African-American patients receiving sipuleucel-T (Provenge) in metastatic castration-resistant prostate cancer and the potential for combinations with this agent.

Dr. Daud Discusses the Current Status of Immunotherapy in Melanoma

August 28th 2017

Adil Daud, MD, clinical professor, Department of Medicine, Helen Diller Family Comprehensive Cancer Center, at University of California, San Francisco, discusses the current status of immunotherapy in melanoma.

Dr. Nastoupil on Efficacy With Pembrolizumab and Rituximab in Follicular Lymphoma

August 28th 2017

Loretta J. Nastoupil, MD, Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses efficacy findings of a study investigating the combination of pembrolizumab (Keytruda) and rituximab (Rituxan) in patients with relapsed follicular lymphoma.

Dr. Diehn on Next Steps With Liquid Biopsies in Lung Cancer

August 25th 2017

Maximilian Diehn, MD, PhD, an assistant professor in the Department of Radiation Oncology, Stanford Medicine, discusses some of the next steps researchers are taking with liquid biopsies in the field of lung cancer.

Dr. Gandara on the MYSTIC Trial for Lung Cancer

August 25th 2017

David R. Gandara, MD, director, Thoracic Oncology Program, professor, senior advisor to director, UC Davis Comprehensive Cancer Center, treasurer, International Association for the Study of Lung Cancer (IASLC), discusses the MYSTIC trial for patients with non-small cell lung cancer (NSCLC)

Dr. Black on the Developments in the Field of Immunotherapy for Bladder Cancer

August 25th 2017

Peter Black, MD, senior research scientist, Vancouver Prostate Centre, associate professor, Department of Urologic Sciences, University of British Columbia, discusses future developments being made in the field of immunotherapy for patients with bladder cancer.

Dr. Erba Discusses Efficacy of CPX-351 in Additional Subsets of AML

August 25th 2017

Harry Erba, MD, PhD, professor of medicine, director, University of Alabama (UAB) Hematologic Malignancy Program, UAB School of Medicine, discusses additional subsets of acute myeloid leukemia (AML) that CPX-351 (Vyxeos) demonstrates efficacy in.

Dr. Roboz on Evolving Paradigms in AML Treatment

August 25th 2017

Gail Roboz, MD, a professor of medicine and director of the Clinical and Translational Leukemia Program at Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses evolving paradigms in treatment of patients with acute myeloid leukemia (AML).

Dr. Tolaney Discusses Neratinib in HER2+ Breast Cancer

August 25th 2017

Sara M. Tolaney, MD, MPH, instructor of medicine, Harvard Medical School, attending physician of medical oncology, Dana-Farber Cancer Institute, discusses neratinib (Nerlynx) in HER2-positive breast cancer.

Dr. Nanus Discusses Early Stage Kidney Cancer Treatment

August 25th 2017

David M. Nanus, MD, medical oncologist, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses treatment for patients with early-stage kidney cancer.

Dr. Grob on the Tolerability and Efficacy of Ipilimumab in Melanoma

August 24th 2017

Jean Jacques Grob, MD, PhD, professor of dermatology at the Hospital de la Timone, discusses the tolerability and efficacy of ipilimumab (Yervoy) for melanoma.